Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul-Aug;16(4):e210-e218.
doi: 10.1097/ADM.0000000000000918. Epub 2021 Sep 22.

First-line Medications for the Outpatient Treatment of Alcohol Use Disorder: A Systematic Review of Perceived Barriers

Caroline Gregory  1 , Yelena Chorny, Shelley L McLeod, Rohit Mohindra
Affiliations

First-line Medications for the Outpatient Treatment of Alcohol Use Disorder: A Systematic Review of Perceived Barriers

Caroline Gregory et al. J Addict Med. 2022 Jul-Aug.

Abstract

Objectives: Alcohol use disorder (AUD) is a common illness with significant health and economic consequences. Although three pharmacotherapeutic agents have been shown to decrease heavy drinking days among individuals with AUD, they are vastly underutilized in clinical practice. The objective of this review was to elucidate barriers that may prevent patients from obtaining medication for addiction treatment (MAT) for AUD in an outpatient or residential setting.

Methods: Electronic searches of Medline and EMBASE were conducted, and reference lists were hand-searched. All study designs which discussed the use of MAT for AUD in an outpatient or residential setting were eligible for inclusion. Two reviewers independently screened the search output to identify potentially eligible articles, the full texts of which were retrieved and assessed for inclusion.

Results: After eliminating duplicate citations and articles that did not meet eligibility criteria, 23 articles were included in the review. Perceived barriers to obtaining pharmacotherapy for the treatment of AUD in an outpatient or residential setting were grouped into 3 themes: lack of knowledge and concerns about efficacy and complexity of prescribing; treatment philosophy and stigma; medication accessibility including formulary restrictions, geographical and socioeconomic barriers.

Conclusions: Although evidence-based pharmacotherapeutics have been approved for the treatment of AUD, our findings suggest patients continue to experience barriers to the use of these medications. Efforts should be made to increase rates of prescribing by providers and the use of medications by patients. More research is needed to further elucidate perceived barriers to MAT use, along with strategies to overcome them.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest.

Comment in

References

    1. Canadian Tobacco Alcohol and Drugs (CTADS) Survey: 2017 summary. Published October 30, 2018. Available at: https://www.canada.ca/en/health-canada/services/canadian-alcohol-drugs-s... . Accessed September 7, 2021.
    1. Hagedorn HJ, Wisdom JP, Gerould H, et al. Implementing alcohol use disorder pharmacotherapy in primary care settings: A qualitative analysis of provider-identified barriers and impact on implementation outcomes. Addict Sci Clin Pract . 2019;14(1):24.
    1. Spithoff S, Turner S, Gomes T, et al. First-line medications for alcohol use disorders among public drug plan beneficiaries in Ontario. Can Fam Physician Med Fam Can . 2017;63(5):e277–e283.
    1. Goh ET, Morgan MY, et al. Review article: pharmacotherapy for alcohol dependence - the why, the what and the wherefore. Aliment Pharmacol Ther . 2017;45(7):865–882.
    1. Jørgensen CH, Pedersen B, Tønnesen H, et al. The efficacy of disulfiram for the treatment of alcohol use disorder. Alcohol Clin Exp Res . 2011;35(10):1749–1758.

Publication types